Altimmune's Liver Drug Gains FDA Breakthrough Status, Eyes MASH Market

GAITHERSBURG, Md. – March 05, 2026 – Altimmune, Inc. has signaled a major step forward for its lead drug candidate, pemvidutide, announcing that the U.S. Food and Drug Administration (FDA) has granted it Breakthrough Therapy Designation for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The announcement, part of the company's 2025 year-end financial report, positions Altimmune to accelerate its push into the highly competitive and lucrative liver disease market, with plans to initiate a pivotal Phase 3 trial in 2026.

The regulatory milestone comes on the heels of positive 48-week data from its Phase 2b IMPACT trial and coincides with a significant strengthening of the company's financial and leadership teams. With a fortified balance sheet and a new CEO with deep experience in liver disease, Altimmune is gearing up for a critical period of late-stage development for a drug that also holds promise for alcohol-related disorders.

“In pemvidutide, we have a unique and differentiated compound with the potential to address critical unmet needs of patients with serious liver diseases such as MASH,” said Jerry Durso, President and Chief Executive Officer of Altimmune, in a statement. “We remain focused on ensuring that we have the means and the capabilities to successfully execute Phase 3 development in MASH and capture the significant opportunities ahead of us.”

A New Contender in the Crowded MASH Arena

The FDA's Breakthrough Therapy Designation is a significant validation for pemvidutide. This status is reserved for drugs intended to treat serious conditions that have shown preliminary clinical evidence of substantial improvement over available therapies. The designation provides more intensive FDA guidance and a potentially expedited development and review timeline, which could shave months or even years off the journey to market.

The decision was based on 24-week data from the IMPACT trial, which demonstrated statistically significant MASH resolution. This was further supported by 48-week data showing continued improvements in key non-invasive markers of liver fibrosis and inflammation, such as Enhanced Liver Fibrosis (ELF) scores. Notably, patients on the 1.8 mg dose of pemvidutide continued to lose weight between the 24 and 48-week marks without signs of plateauing, a compelling feature for a disease closely linked to obesity.

Pemvidutide is a dual-agonist that targets both the glucagon and GLP-1 receptors in a balanced 1:1 ratio. This mechanism is designed to attack MASH from two angles: the GLP-1 action helps suppress appetite and drive weight loss, while the glucagon action works directly on the liver to reduce fat, inflammation, and fibrosis.

However, Altimmune enters a fiercely competitive landscape. Madrigal Pharmaceuticals' Rezdiffra became the first FDA-approved MASH treatment in 2024, setting a benchmark for efficacy. Other major pharmaceutical players are close behind. Boehringer Ingelheim and Zealand Pharma's survodutide, another glucagon/GLP-1 agonist, also holds a Breakthrough Therapy Designation and has shown impressive MASH resolution rates in its own trials. Meanwhile, giants like Eli Lilly are exploring their blockbuster weight-loss drugs for MASH, and Viking Therapeutics is advancing its own candidate. For pemvidutide to succeed, it will need to demonstrate clear clinical differentiation in its upcoming Phase 3 trial, which Altimmune confirmed is aligned with FDA expectations following a successful end-of-phase-2 meeting.

Fortifying the Foundation for a Pivotal Phase

To navigate this challenging environment, Altimmune has made significant strategic moves to solidify its corporate and financial footing. The company appointed Jerry Durso as CEO, a life sciences veteran with over 30 years of experience. His tenure as CEO of Intercept Pharmaceuticals, where he developed a successful franchise in rare liver disease before its acquisition, provides direct and highly relevant experience for steering Altimmune's path forward.

This leadership change is backed by a newly fortified balance sheet. Altimmune ended 2025 with $274 million in cash, cash equivalents, and short-term investments. This position was further bolstered in January 2026 by a $75 million registered direct offering and an additional $8 million raised through its at-the-market facility. The company now reports a pro forma cash position of approximately $340 million as of late February 2026.

This financial runway is critical, as Phase 3 trials are notoriously long and expensive. The company's net loss for 2025 was $88.1 million, and expenses are expected to climb as it launches the global MASH trial. Altimmune's management expressed confidence that its current cash reserves are sufficient to fund operations through 2028, covering the entirety of the planned Phase 3 MASH trial and other ongoing studies.

Beyond MASH: Tackling Addiction and Alcohol-Related Liver Disease

While MASH is the main event, Altimmune is also exploring pemvidutide's potential in other areas of significant unmet need: Alcohol Use Disorder (AUD) and Alcohol-associated Liver Disease (ALD). This strategic diversification leverages the drug's unique mechanism and could open substantial new markets.

The RECLAIM Phase 2 trial is evaluating pemvidutide in patients with AUD, with topline data expected in the third quarter of 2026. This readout is a major anticipated catalyst for the company. There is a growing body of evidence suggesting that GLP-1 agonists can reduce cravings and consumption of alcohol, and Altimmune hopes pemvidutide's dual action will prove effective. With millions affected by AUD and limited effective pharmacological options, a successful therapy would be a major breakthrough.

Simultaneously, the RESTORE Phase 2 trial is enrolling patients with ALD, a condition where pemvidutide's direct effects on liver fat and inflammation could be particularly beneficial. Success in these indications would not only provide new treatment options for devastating conditions but also significantly broaden pemvidutide's therapeutic profile, positioning it as a versatile treatment for a spectrum of metabolic and liver-related diseases.

With regulatory validation in hand, a clear path to Phase 3 for its lead indication, a strong cash position, and experienced leadership at the helm, Altimmune is moving into a defining period. The coming months will be crucial in determining whether this dual-action therapy can deliver on its considerable promise for patients worldwide.